Bbg Advanced Therapies

“Biobridge global is the sole member of the corporation.”

“Written actions by the governing body: meetings held and written actions undertaken were documented in the minutes of the meetings of biobridge global's board of directors.”

“Form 990: the organization engages an outside accounting firm to prepare the form 990. Once prepared, the return is reviewed by the financial management staff from biobridge global, a related organization. A copy of the form 990 is provided to the executive committee of the board of directors of biobridge global prior to filing.”

“Of interest policy: a copy of the organization's conflict of interest policy is provided annually to all officers, key employees and board of directors of biobridge global. In addition, questionnaires are given out on an annual basis to all officers, key employees and board of directors which cover business and family relationships and various activities that have occurred over the course of the year. Every attempt is made to ensure that all forms are returned. Individuals who fail to return the requested forms or provide incomplete information are contacted by the organization.”

“Management compensation: in determining the top manegement official's compensation, the organization relied on biobridge global's process to assist in compensation decisions. The process of determining the top manegement compensation is disclosed on their form 990.”

“Officer's compensation: the organization relied on biobridge global's process to assist in compensation decisions. The process of determining other officer's compensation is disclosed on their form 990.”

“With taxable entities: the organization has not established written procedures but is committed to ensuring that any arrangements entered into safeguard the organization's exempt status and will consult with legal counsel when necessary. All contracts entered into by the organization are reviewed by biobridge global's general legal counsel to ensure the terms of the agreements do not jeopardize the organization's exemption and furthers its mission.”

“Available to the public: any documents subject to open record requirements are made available upon request.”

“Description of organization's mission or most significant activities: by providing end-to-end capabilities in cgmp biomanufacturing experience and clinical research support. Gencure focuses on regenerative medicine through the texas cord blood bank, a biomanufacturing facility, an apheresis center and a deceased donor tissue bank.”

“In 2020, GenCure Tissue Center collaborated with a local transplant center, OPO, and eye bank to open a central hub for organ, eye, and tissue recovery. Use of the dedicated tissue recovery suite streamlined the recovery process and improved donation outcomes by reducing chances of tissue contamination. It also allowed staff to continue recovery efforts while reducing their exposure to COVID- 19 during the pandemic. Enhancements were also made to the training of tissue recovery staff to improve technical skills. One notable outcome of these efforts was recognition of GenCure's tissue recovery team as the nation's top program for recovering femoral vascular tissue by its cardiovascular tissue processing partner. GenCure's Tissue team also improved its grief support services by offering digital resources and virtual support programs for donor families to participate in during while in-person events were unavailable during the pandemic. The Center for Apheresis & Therapeutic Services added 4,582 new donors to the Be The Match registry in 2020 and facilitated 106 stem cell and marrow donations to patients in need here and abroad. The Cord Blood program collected 929 cord blood units for the year, 39 of which were banked and 304 units that were made available for research and development. Eleven units were shipped for transplant for patients ranging from one year to 67 years old. While currently offering a birth tissue donation program (placenta and cord), the Texas Cord Blood Bank provided 972 placentas to our processing partners to be used as grafts for treatment of injuries such as burns and diabetic foot ulcers. The GenCure Biomanufacturing Center enables progress in the field of advanced therapies by offering process and analytical development, cGMP manufacturing, in-process and release testing, while leveraging a unified quality management system. We partner with our customers with the end goal of clinical development and commercialization in mind. The first phase of GenCure's clinical scale biomanufacturing facility opened in March 2020 in the heart of San Antonio, at the VelocityTX Innovation Center. The biomanufacturing space is compliant with FDA regulations, EU Annex 1 and PMDA (Grade A, B, C, D). Cleanrooms are sized for a wide range of production volumes, up to a series of 250L bioreactors. This facility includes an initial 6,700 square feet of cleanroom production space, a 2,500-square-foot development lab, along with office and meeting space.”